相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Chemokines and cancer: new immune checkpoints for cancer therapy
Nathan Karin
CURRENT OPINION IN IMMUNOLOGY (2018)
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
Bai Liu et al.
CYTOKINE (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Tumor-experienced NK cells inhibit T cell proliferation and activation through PD-L1
Jessica M. Sierra et al.
CANCER RESEARCH (2018)
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Benjamin Y. Jin et al.
JCI INSIGHT (2018)
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
M. Felices et al.
GYNECOLOGIC ONCOLOGY (2017)
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAIVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Charles J. Rosser et al.
JOURNAL OF UROLOGY (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley et al.
LANCET ONCOLOGY (2017)
ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
Arjan Kol et al.
ONCOTARGET (2017)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Caroline Jochems et al.
ONCOTARGET (2017)
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
Jonathan K. Fallon et al.
ONCOTARGET (2017)
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
Dimitrios Mathios et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode et al.
CANCER IMMUNOLOGY RESEARCH (2016)
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab
Swati Khanna et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
Peter S. Kim et al.
ONCOTARGET (2016)
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-Li expression.
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ
Yin Guo et al.
JOURNAL OF IMMUNOLOGY (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
IFN-γ regulates survival and function of tumor-induced CD11b+Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1
Jose Medina-Echeverz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin
John P. Sfakianos et al.
JOURNAL OF UROLOGY (2014)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
Jessica Ann Chacon et al.
PLOS ONE (2013)
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity
Hing C. Wong et al.
ONCOIMMUNOLOGY (2013)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Lishomwa C. Ndhlovu et al.
BLOOD (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
Ping Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
Jesus Garcia-Foncillas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu et al.
CLINICAL CANCER RESEARCH (2010)
Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial
Merrill S. Kies et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Novel Human Interleukin-15 Agonists
Xiaoyun Zhu et al.
JOURNAL OF IMMUNOLOGY (2009)
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Role of IFN-γ in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4+ Tregs
Zhaojun Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
J Marks-Konczalik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
